Summary & Overview
HCPCS J0600: Injection, Edetate Calcium Disodium, Up to 1000 mg
HCPCS Level II code J0600 designates an injectable dose of edetate calcium disodium (up to 1000 mg). This drug-specific HCPCS code is used when billing for the medication product administered intravenously or by other parenteral routes in outpatient infusion centers, hospital outpatient departments, and physician office settings. Nationally, drug-specific HCPCS codes like J0600 matter because they drive payers' coverage, pricing, and reporting for parenteral therapies and can affect site-of-care cost differentials.
Key payers in this national overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical purpose and service context, an outline of common payer coverage considerations, and typical billing elements tied to HCPCS Level II drug reporting. The publication also summarizes benchmarks and policy updates relevant to parenteral drug billing, clinical context for use of edetate calcium disodium, and common procedural relationships that influence reimbursement and utilization tracking. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0600 represents an injection of edetate calcium disodium, dosed up to 1000 mg. This HCPCS Level II code describes a specific parenteral drug administration and is used to bill for the medication product rather than the injection procedure itself.
Service Type: Drug administration (injectable medication)
Typical Site of Service: Outpatient infusion or injection settings, including infusion centers, hospital outpatient departments, and physician offices where parenteral medications are administered.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with chronic lead exposure presents to an outpatient infusion center for chelation therapy using edetate calcium disodium. The patient has elevated blood lead levels and symptoms of peripheral neuropathy and hypertension attributable to lead toxicity. Prior to treatment, the clinician reviews recent laboratory studies (serum creatinine, complete metabolic panel), documents baseline vitals and neurovascular exam, obtains informed consent, and confirms vascular access (peripheral IV or PICC). The typical workflow includes medication preparation by pharmacy, verification of dosage (up to 1000 mg per billing unit J0600), administration via slow intravenous infusion under nursing observation, monitoring for adverse reactions (hypocalcemia, hypotension, allergic reaction), and post-infusion observation with discharge instructions. This service is commonly delivered in an outpatient infusion center, hospital outpatient department, or specialized occupational medicine clinic. Medical necessity is supported by toxicology testing and documentation of clinical signs consistent with heavy metal poisoning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of a single-dose vial of edetate calcium disodium is discarded and documentation supports wasted amount. |